What is Eczema?
Eczema is a chronic inflammatory skin condition, characterized by dry skin with red and itchy patches. Atopic dermatitis (AD) is the most common type of eczema. The word “atopic” refers to a collection of diseases involving the immune system, and the word “dermatitis” means inflammation of the skin. Eczema can range from mild, when patches of skin are slightly dry, itchy, and red, to severe, when patches of skin are extremely irritated, cracked, and oozing. Eczema most often develops in childhood and may or may not continue into adulthood. People with eczema often experience periods of time when their condition flares up, often triggered by environmental factors such as the weather, certain foods, stress, hormones, irritants, and allergens.
- Topical corticosteroids
- Oral steroids
- Topical calcineurin inhibitors
- Antibiotics to treat secondary skin infections
- Moisturizers and emollients
- Coal tar
A randomized, double-blind, multi-center, parallel-group, placebo-controlled dose-ranging study to assess the efficacy and safety of nemolizumab (CD14152) in moderate-to-severe atopic dermatitis subjects with severe pruritus receiving topical corticosteroids
- Age 18 years or over
- Moderate to severe atopic dermatitis
- 24 weeks of treatment with topical corticosteroids and either nemolizumab injections or placebo
- Approximately 12 clinic visits over a period of about 36 weeks
We currently do not have any upcoming eczema clinical trials. Please see our recruiting eczema trials or contact us to be placed on a contact list for our next available clinical trial.